<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Nordisk &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/nordisk/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Thu, 06 Mar 2025 05:05:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>Nordisk &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Novo Nordisk offers Wegovy for lower than half of the worth</title>
		<link>https://bloggingthree.soflytech.com/2025/03/novo-nordisk-offers-wegovy-for-lower-than-half-of-the-worth/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 06 Mar 2025 05:05:20 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[offers]]></category>
		<category><![CDATA[Price]]></category>
		<category><![CDATA[Wegovy]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=25723</guid>

					<description><![CDATA[Novo Nordisk On Wednesday it can offer its weight reduction medication for lower than half of its usual price per 30 days New online pharmacy from Direct-to-Consumer. The variety of money The offer is accessible to tens of millions of patients without insurance coverage for the blockbuster injection. The aim is to make more people [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    On Wednesday it can offer its weight reduction medication for lower than half of its usual price per 30 days <a href="https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html" target="_blank">New online pharmacy from Direct-to-Consumer</a>.</p>
<p>The variety of money<strong> </strong>The offer is accessible to tens of millions of patients without insurance coverage for the blockbuster injection. The aim is to make more people available and at the identical time be sure that the patients use the brand medication as an alternative of cheaper, compiled imitators that became an increasing number of popular during a recently dissolved US deficiency in Novo Nordisk&#39;s medication.</p>
<p>The pharmacy called Novocare enables the patient to pay 499 US dollars in money per 30 days for the weekly medication. The List Prize from Wegovy before insurance and other discounts is nearly <a href="https://www.novocare.com/obesity/products/wegovy/let-us-help/explaining-list-price.html" target="_blank">$ 1,350 per 30 days</a>.</p>
<p>The site may also send Wortovy recipes on to the patients&#39; houses via a special practice partner. Among other things, Novocare also offers refill memories and access to live support from an organization manager of the corporate, including.</p>
<p>&#8220;Patients and prescribers have a different option that offers a convenient access to all cans of real, approved path approved by the FDA at a lower cost in our high-quality pen,&#8221; said Dave Moore, Executive Vice President of US operations and global business development.</p>
<p>In particular, the corporate said within the &#8220;near future&#8221; that the brand new savings offer for Wegven to make use of money paid patients who use traditional retail pharmacies will expand in order that they may also pay a less expensive price.</p>
<p>The step of the Danish drug broker follows the same strategy of his major competitor <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-4">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>. The two corporations are fighting to dominate the so-called GLP-1S market, which mimic certain intestinal hormones to suppress the appetite and regulate blood sugar.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">More CNBC medical health insurance</h2>
</div>
</div>
</div>
</div>
<div class="group">
<p>In January 2024, Eli Lilly launched her own online pharmacy from Direct-to Consumer, Lillydirect, to assist patients access his weight reduction drug Zepbound.</p>
<p>The website enables justified patients to receive a prescription through a telemedicine provider and will be delivered at home. Lillydirect has also offered Zepbound in single dose vials, which is half and even lower than the standard monthly list price of $ 1,000.</p>
<p>In the past few months, the Food and Drug Administration has explained the US lack of Zepbound and the pathway concerning the US deficiency. This decision prevents certain connecting pharmacies from creating non -approved versions of the injections.</p>
<p>Novocare helps patients &#8220;to avoid the considerable risks that can be equipped by the compounding market, as warned by respected organizations, experts in the medical community and the FDA,&#8221; said Novo Nordisk in a press release.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-2">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Do not miss these findings from CNBC Pro</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107424999-1717670576134-gettyimages-2141945487-porzycki-wegovyph240408_npUqb.jpeg?v=1741181769&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Novo Nordisk shares rise 8% after Wegovy sales beat expectations</title>
		<link>https://bloggingthree.soflytech.com/2024/11/novo-nordisk-shares-rise-8-after-wegovy-sales-beat-expectations/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Mon, 11 Nov 2024 21:55:55 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[beat]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[rise]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[Wegovy]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=18963</guid>

					<description><![CDATA[Novo Nordisk on Wednesday reported a third-quarter sales increase for its blockbuster weight-loss drug Wegovy and lowered its full-year 2024 growth forecast. The company&#39;s shares jumped early Wednesday and were last up 7.7% at 9:02 a.m. London time. The Danish pharmaceutical giant said its third-quarter net profit reached 27.3 billion Danish kroner ($3.92 billion), above [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Novo Nordisk on Wednesday reported a third-quarter sales increase for its blockbuster weight-loss drug Wegovy and lowered its full-year 2024 growth forecast.</p>
<p>The company&#39;s shares jumped early Wednesday and were last up 7.7% at 9:02 a.m. London time.</p>
<p>The Danish pharmaceutical giant said its third-quarter net profit reached 27.3 billion Danish kroner ($3.92 billion), above the general LSEG estimate of 26.95 billion Danish kroner.</p>
<p>Novo Nordisk added that Wegovy&#39;s third-quarter sales rose 79% year-on-year and amounted to 17.3 billion Danish crowns. This was above the 15.9 billion Danish crowns that analysts had expected, in accordance with a consensus prepared by the corporate, Reuters reported.</p>
<p>The company narrowed its full-year 2024 revenue growth forecast to 23% to 27% from 22% to twenty-eight% at constant exchange rates and tightened its operating profit growth forecast to 21% to 27%, up from the previously expected 20% to twenty-eight%, each at constant exchange rates.</p>
<p>The forecast reflected the corporate&#39;s expectations for sales growth in North America and internationally, driven largely by volume growth of glucagon-like peptide-1 (GLP-1)-based treatments, Novo Nordisk said.</p>
<p>“Following unexpectedly high volume growth in recent years, including GLP-1 based products such as Ozempic and Wegovy, coupled with the expectation of continued volume growth and capacity constraints at some manufacturing sites, the outlook also reflects expected continued regular supply constraints and related Drug shortage reports for a range of products and regions,” she added.</p>
<p>Novo Nordisk added that it&#8217;s investing in capability each internally and externally to extend supply within the short and long run.</p>
<p>Regionally, Novo Nordisk&#39;s revenue in North America increased 22% yr over yr within the third quarter of 2024. Sales in the important thing US market rose 21% within the period, with GLP-1 volumes within the region increasing 15%.</p>
<p>“Novo Nordisk is the market leader with 53.9% in terms of total monthly prescriptions and 50.0% in terms of new brand prescriptions,” the corporate said.</p>
<p>The health titan has faced increasing competition, but has also received promising news in the burden loss space in recent months.</p>
<p>Last week, the U.S. Food and Drug Administration said all doses of Wegovy were now available within the U.S., after previously noting that the bottom dose of Wegovy was briefly supply. The news was seen as a signal that Novo Nordisk&#39;s efforts to extend supplies of Wegovy and diabetes drug Ozempic are paying off.</p>
<p>Also in October, a study showed that Ozempic may reduce the danger of developing Alzheimer&#39;s disease, suggesting it could delay or prevent the memory-robbing condition.</p>
</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107384064-1709830398609-gettyimages-1830849279-porzycki-ozempicp231207_npYtz.jpeg?v=1726852410&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>‘Stop ripping us off’: Novo Nordisk CEO defends weight-loss drug prices during Senate hearing</title>
		<link>https://bloggingthree.soflytech.com/2024/09/stop-ripping-us-off-novo-nordisk-ceo-defends-weight-loss-drug-prices-during-senate-hearing/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Tue, 24 Sep 2024 17:50:16 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Defends]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[hearing]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[ripping]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[stop]]></category>
		<category><![CDATA[weightloss]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=15651</guid>

					<description><![CDATA[Novo NordiskThe top manager faced a Interrogation by the Senate on Tuesday over high prices for the corporate&#39;s weight-loss drug Wegovy and diabetes drug Ozempic, as demand for each injections soars within the U.S. Lars Fruergaard Jørgensen, CEO of Novo Nordisk, made no explicit commitment Legislators within the Senate Committee on Health, Education, Labor and [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>The top manager faced a <a href="https://www.help.senate.gov/chair/newsroom/press/media-advisory-sanders-to-lead-help-committee-hearing-on-outrageous-ozempic-and-wegovy-prices-with-novo-nordisk-ceo" target="_blank" rel="noopener">Interrogation by the Senate</a> on Tuesday over high prices for the corporate&#39;s weight-loss drug Wegovy and diabetes drug Ozempic, as demand for each injections soars within the U.S. </p>
<p>Lars Fruergaard Jørgensen, CEO of Novo Nordisk, made no explicit commitment<strong> </strong>Legislators within the Senate Committee on Health, Education, Labor and Pensions<a href="https://www.help.senate.gov/chair/newsroom/press/media-advisory-sanders-to-lead-help-committee-hearing-on-outrageous-ozempic-and-wegovy-prices-with-novo-nordisk-ceo" target="_blank" rel="noopener"> hearing</a> in Washington, DC, that he would lower the costs of the 2 drugs.</p>
<p>But Jørgensen said he desires to work with them on policy solutions that address the &#8220;structural problems&#8221; that drive up prescription drug costs. He also promised to sit down down with pharmacy profit managers &#8211; middlemen who negotiate drug discounts with manufacturers on behalf of insurers &#8211; to &#8220;work together on anything that will give patients access and affordability to medicines.&#8221;</p>
<p>The commitment got here after Senator Bernie Sanders, the independent senator from Vermont who chairs the Senate committee, said he had received written commitments from all major PBMs that they&#8217;d not limit coverage of Wegovy and Ozempic if Novo Nordisk lowered its list prices.<strong> </strong>The hearing comes about five months after Sanders launched an investigation into the Danish pharmaceutical company&#39;s pricing practices. </p>
<p>&#8220;All we&#39;re saying, Mr. Jørgensen, is that you should treat the American people the same way you treat people around the world,&#8221; Sanders said during Tuesday&#39;s hearing. &#8220;Stop ripping us off.&#8221;</p>
<p>He identified that Novo Nordisk had generated nearly $50 billion in revenue from Wegovy and Ozempic, with the vast majority of that revenue coming from the United States. Sanders claims that Novo Nordisk charges Americans significantly higher prices for its blockbuster drugs than patients in other countries. Before insurance costs, Ozempic costs nearly <a href="https://www.novocare.com/diabetes/products/ozempic/explaining-list-price.html" target="_blank" rel="noopener">$969 monthly</a> and Wegovy costs almost <a href="https://www.novocare.com/obesity/products/wegovy/let-us-help/explaining-list-price.html" target="_blank" rel="noopener">$1,350 monthly</a> within the USA </p>
</div>
<div class="group">
<p>In some European countries, each treatments can now be offered for lower than $100 monthly, in line with a press release from the <a href="https://www.help.senate.gov/chair/newsroom/press/media-advisory-sanders-to-lead-help-committee-hearing-on-outrageous-ozempic-and-wegovy-prices-with-novo-nordisk-ceo" target="_blank" rel="noopener">Committee</a>Ozempic costs only $59 in Germany, while Wegovy costs $92 within the UK.</p>
<p>Sanders also said last week that CEOs of major generic pharmaceutical corporations had told him they may develop a version of Ozempic for <a href="https://www.sanders.senate.gov/press-releases/news-sanders-announces-generic-pharma-companies-willing-to-sell-ozempic-for-less-than-100/" target="_blank" rel="noopener">lower than $100 monthly</a> with profit. There are currently no generic alternatives to Ozempic available within the US </p>
<p>Large PBMs, including <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-10">UnitedHealth Group<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>&#39;s Optum Rx and <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-11">CV<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>Caremark and a few health insurers said list prices of $100 monthly for Wegovy and Ozempic would help make these drugs more widely available to patients, in line with a <a href="https://www.sanders.senate.gov/wp-content/uploads/9.23.2024-Novo-Nordisk-Untenable-Strategy-final.pdf" target="_blank" rel="noopener">release</a> by Sanders.</p>
<p>That could undermine Jørgensen&#39;s claim in his written testimony that the PBMs are answerable for the high list prices of Novo Nordisk&#39;s drugs and &#8220;exercise almost total control over ensuring that hundreds of millions of Americans get the medicines they need at affordable prices.&#8221; The company argues that it must give you the option to pay rebates to those middlemen to get their drugs on drug lists, or lists of medicine covered by insurance firms.</p>
<p>Jørgensen noted that the written guarantees Sanders received from the PBMs were &#8220;new information to me,&#8221; but said he could understand &#8220;that the PBMs may have changed their minds.&#8221;</p>
<p>Novo Nordisk argues that it has invested billions in researching, developing and expanding production of those drugs, and is pouring even extra money into researching their potential to treat other obesity-related diseases. This investment has prolonged and improved the lives of thousands and thousands of Americans, helping to cut back health care costs related to obesity and diabetes, in line with Jørgensen&#39;s written testimony.</p>
</div>
<div class="group">
<p>During the hearing, Jørgensen said the corporate had fought to have the drugs covered by private and non-private health insurers.</p>
<p>He also blamed the &#8220;complex U.S. health care system&#8221; partly for making it difficult for patients to get inexpensive pharmaceuticals, noting that &#8220;no single company alone can solve such enormous and complicated policy challenges.&#8221;</p>
<p>Jørgensen promised that Novo Nordisk would &#8220;remain committed and work with this committee on policy solutions to address the structural problems that are driving up costs.&#8221;</p>
<p>However, Jørgensen believed that a price reduction could have consequences because it may lead to a discount in insurance coverage.</p>
<p>In his written testimony, Jørgensen said Novo Nordisk&#39;s insulin product, Levemir, was previously available to 90 percent of U.S. patients through drug lists. But after Novo Nordisk lowered the list price, insurers began to stop covering the insulin, leaving only 36 percent of patients with access.</p>
<p>This ultimately prompted the corporate to stop producing the insulin, Jørgensen said in his written statement.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">More health reports from CNBC</h2>
</div>
</div>
</div>
</div>
<div class="group">
<p>Sanders and other lawmakers, <a href="https://www.hsph.harvard.edu/news/hsph-in-the-news/weight-loss-drug-costs-could-go-out-of-control-says-expert/" target="_blank" rel="noopener">Health experts</a> and insurers have warned that insatiable demand for Novo Nordisk’s drugs and similar weight-loss and diabetes treatments from rival <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-14">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    could<a href="https://www.sanders.senate.gov/in-the-news/sanders-diabetes-and-weight-loss-drugs-could-bankrupt-u-s-health-care-system/#:~:text=If%20half%20of%20all%20Medicare,drugs%20in%202022%2C%20%24175%20billion." target="_blank" rel="noopener"> potential bankruptcy of the US healthcare system</a> unless prices fall.</p>
<p>Both drug corporations make GLP-1 drugs that mimic hormones produced within the gut to curb appetite and regulate blood sugar. Eli Lilly&#39;s weight-loss injection Zepbound and diabetes drug Mounjaro also cost around $1,000 a month, before insurance and other subsidies.</p>
<p>In a press release, the Senate Health Committee said it will cost the U.S. $411 billion a yr if half of all Americans took weight-loss drugs made by Novo Nordisk and Eli Lilly. That&#39;s $5 billion greater than Americans will spend on all pharmaceuticals in 2022. </p>
<p>Medicare spending <a href="https://www.kff.org/policy-watch/medicare-spending-on-ozempic-and-other-glp-1s-is-skyrocketing/" target="_blank" rel="noopener">4.6 billion dollars for Ozempic</a> in 2022 alone, in line with the health policy research organization KFF. </p>
<p>Other insurers and employers have implemented strict requirements to regulate the fee of weight-loss drugs or have stopped covering these treatments altogether. Many health plans cover GLP-1 drugs for diabetes but not for weight reduction. The federal Medicare program doesn&#8217;t cover weight-loss treatments unless they&#8217;re approved and prescribed for one more condition. </p>
<p>The hearing comes because the Biden administration and lawmakers on each side seek to contain health care costs within the United States, including by pressuring<strong> </strong>the pharmaceutical industry and the middlemen within the drug supply chain. On average, Americans pay two to 3 times more for pharmaceuticals than patients in other industrialized countries, in line with a <a href="https://www.whitehouse.gov/briefing-room/statements-releases/2023/12/14/fact-sheet-biden-harris-administration-announces-dozens-of-pharma-companies-raised-prices-faster-than-inflation-triggering-medicare-rebates/" target="_blank" rel="noopener">Profile</a> from the White House.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-2">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these insights from CNBC PRO</h2>
</div>
</div>
</div>
</div>
<div class="group">
<p>Notably, Ozempic will likely be subject to the subsequent round of price negotiations between manufacturers and Medicare &#8211; a key provision of President Joe Biden&#39;s Inflation Reduction Act geared toward lowering costs for seniors. Wall Street analysts say Ozempic will likely be eligible for negotiations until the subsequent round of medicine is chosen in 2025, for price changes that take effect in 2027.</p>
<p>The lawmakers called on Novo Nordisk to commit to not sue the federal government if Ozempic and Wegovy are chosen for the subsequent round of negotiations.</p>
<p>Jørgensen didn&#8217;t make this commitment explicit, noting that the corporate believes the talks are &#8220;not fair negotiations, but in reality price fixing&#8221; that could have negative consequences for drug innovation.</p>
</div>
<div role="region" aria-labelledby="Placeholder-ArticleBody-Video-108038394">
<div role="button" tabindex="0" id="Placeholder-ArticleBody-Video-108038394" class="PlaceHolder-wrapper" data-vilynx-id="7000352709" data-test="VideoPlaceHolder">
<div class="InlineVideo-videoEmbed" id="InlineVideo-0" data-test="InlineVideo">
<div class="InlineVideo-wrapper">
<div class="InlineVideo-inlineThumbnailContainer"><img decoding="async" class="InlineVideo-videoThumbnail" src="https://image.cnbcfm.com/api/v1/image/108038395-17271905911727190589-36390044904-1080pnbcnews.jpg?v=1727190591&#038;w=750&#038;h=422&#038;vtcrop=y" alt="Novo Nordisk CEO testifies before Senate on weight loss drug prices"><span class="InlineVideo-videoButton"></span><span></span></div>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108038385-17271896822024-09-24t143327z_1659986463_rc217aa6zif3_rtrmadp_0_usa-congress-novo.jpeg?v=1727189733&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Health &#124; How Denmark persuaded domestic giant Novo Nordisk to chop Ozempic prices</title>
		<link>https://bloggingthree.soflytech.com/2024/08/health-how-denmark-persuaded-domestic-giant-novo-nordisk-to-chop-ozempic-prices/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sat, 17 Aug 2024 23:12:29 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cut]]></category>
		<category><![CDATA[Denmark]]></category>
		<category><![CDATA[Domestic]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[Ozempic]]></category>
		<category><![CDATA[persuaded]]></category>
		<category><![CDATA[prices]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=12245</guid>

					<description><![CDATA[By Arthur Allen, KFF Health News On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a number one Danish newspaper, urging the Danish company to live as much as its altruistic standards and lower U.S. prices for its successful diabetes and weight-loss drugs. What Sanders [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div>
<p class="krtByline"><strong>By Arthur Allen, KFF Health News</strong></p>
<p class="krtText">On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a number one Danish newspaper, urging the Danish company to live as much as its altruistic standards and lower U.S. prices for its successful diabetes and weight-loss drugs.</p>
<p class="krtText">What Sanders didn&#39;t know was that Denmark, a rustic of six million people, was fighting its own crisis over the financing of Novo Nordisk&#39;s drugs Ozempic and Wegovy.</p>
<p class="krtText">Most other developed countries, including Denmark, negotiate drug costs for his or her residents and pay prices which might be a fraction of those within the United States. But if a drug is effective and expensive, pharmaceutical corporations can clamp down on pricing. And Novo Nordisk did so, not less than initially, pushing the Danish health care system to its limits.</p>
<figure class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class="wp-image-10939925 size-large" src="https://www.mercurynews.com/wp-content/uploads/2024/08/GettyImages-1741637127.jpg" alt="FRANCE-PHARMACEUTICAL-DRUG-HEALTH" width="1024" height="682"><figcaption class="wp-caption-text">This Oct. 23, 2023, file photo shows Ozempic drug boxes, an injectable antidiabetic drug, at a pharmacy in Riedisheim, eastern France. (Photo by SEBASTIEN BOZON/AFP via Getty Images) </figcaption></figure>
<p class="krtText">The country&#39;s public health system had adopted Ozempic as a diabetes drug for years, but in 2022 doctors began prescribing it for weight reduction as well, and shortly &#8220;they emptied all the coffers of the entire public health system,&#8221; said Jens Juul Holst, a professor on the University of Copenhagen and co-inventor of the drug.</p>
<p class="krtText">Countries all over the world are fighting how and when to pay for Ozempic, Eli Lilly&#39;s Mounjaro and other drugs in the identical chemical class, especially when prescribed for weight reduction. In fact, the astronomically high prices within the U.S. set a bar that pharmaceutical corporations can use of their negotiations with other health systems.</p>
<p class="krtText">In Denmark, where prescriptions for these drugs will devour 18 percent of the regional pharmaceutical budget in 2023, officials considered the unthinkable in a system that prides itself on free cradle-to-grave care: forcing patients to pay for Ozempic—a drug manufactured within the country—out of their very own pockets.</p>
<p class="krtText">In America, stricter insurance policies are making it increasingly difficult for patients to acquire the medications, which may cost as much as $1,350 a month.</p>
<p class="krtText">&#8220;In our clinic, there are month-to-month changes in terms of care, coverage and available drugs,&#8221; said Michael Blaha, director of clinical research on the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. He said doctors and patients play &#8220;a constant game of prior authorizations and appeals.&#8221;</p>
<aside class="related left"></aside>
<p class="krtText">The use of the drugs for weight reduction is a very sensitive issue. Novo Nordisk and Lilly are fighting for reimbursement &#8211; backed by some doctors and patient groups, lots of whom are funded by the drug corporations. They are pushing to overturn a 2005 federal regulation that prohibits Medicare from reimbursing weight-loss treatments.</p>
<p class="krtText">&#8220;There&#39;s a strong likelihood that Medicare will cover these obesity drugs sooner or later,&#8221; said David Kim, an assistant professor of drugs and public health on the University of Chicago. If Medicare pays, he added, private insurers will likely follow suit.</p>
<p class="krtText">The impact on government and personal insurance budgets, he said, depends upon three unanswered questions: How many individuals will ultimately get the drugs? How long will they take them? And at what cost?</p>
<p class="krtText">The potential Medicare market alone is big. In 2020, about 13.7 million Medicare beneficiaries, a few quarter of the entire, were diagnosed as obese or obese, in keeping with Juliette Cubanski and Tricia Neuman, researchers at KFF, a nonprofit health information organization that features KFF Health News. Assuming a 50% discount on Wegovy&#39;s $1,300 monthly list price, that involves $107 billion. The total federal share of Medicare Part D spending in 2024 has been estimated at $120 billion.</p>
<p class="krtText">Novo Nordisk has spent $7.6 million lobbying Congress over the past 12 months, and lobbying disclosures show that the vast majority of that cash was used to push bills within the House and Senate to expand the usage of GLP-1 drugs.</p>
<p class="krtText">The pressure from pharmaceutical corporations is relentless. Pfizer, which has a GLP-1 drug in development, commissioned a white paper from the consulting firm Manatt arguing that Medicare law already allows coverage of those obesity drugs because they provide advantages beyond weight reduction. Novo and other pharmaceutical corporations have funded studies showing that taking these drugs results in savings in health look after chronic diseases.</p>
<p class="krtText">But the Congressional Budget Office, whose estimates of the prices of such measures are crucial as to whether they&#8217;re ultimately implemented, has not yet issued a final statement. In a presentation in March, the office said it was &#8220;not aware of any empirical evidence directly linking the use of obesity drugs to reductions in other health care spending.&#8221;</p>
<p class="krtText">Prime Therapeutics, a pharmacy reimbursement manager whose clients are employers that sponsor drug plans, released a study this 12 months that found that only a 3rd of patients who take a GLP-1 drug take it for a full 12 months. That means getting insurance firms to cover the drugs can sometimes be a waste of cash, said Patrick Gleason, chief research officer at Prime Therapeutics, because research shows that patients are likely to regain weight after stopping the drugs.</p>
<p class="krtText">This does not likely surprise Danish scientist Holst. He says that for many individuals, appetite suppression through GLP-1 drugs is &#8220;so miserably boring that they can no longer stand it and have to go back to their old lives.&#8221;</p>
<p class="krtText">One answer could possibly be weight reduction programs that use GLP-1 for a 12 months, for instance, followed by maintenance therapy with cheaper drugs, Kim says.</p>
<p class="krtText">Either way, many experts in the sector say it is sensible to start out shedding weight before obesity-related chronic diseases equivalent to type 2 diabetes develop.</p>
<p class="krtText">Because obesity is related to so many comorbidities, pharmaceutical manufacturers are currently conducting studies showing that GLP-1 drugs even have a positive effect on conditions equivalent to sleep apnea and heart, liver and kidney disease.</p>
<p class="krtText">But even those that support the usage of these drugs acknowledge that there&#8217;s uncertainty about how long it takes for the health-promoting effects to take effect and whether shorter-term use can prevent or alleviate longer-term illnesses.</p>
<p class="krtText">&#8220;Modeling the impact is complicated,&#8221; says Alison Sexton Ward, a researcher on the Schaeffer Center for Health Policy and Economics on the University of Southern California. &#8220;Medical costs will not fall immediately. The diseases prevented may not appear for years.&#8221;</p>
<p class="krtText">Starting next 12 months, out-of-pocket costs for Part D Medicare enrollees can be capped at $2,000, meaning U.S. taxpayers could have to cover most Medicare drug costs. So it&#39;s no surprise that the Congressional Budget Office expects the administration to start Medicare price negotiations for semaglutide under the Inflation Reduction Act &#8220;within the next few years,&#8221; in keeping with its March presentation.</p>
<p class="krtText">Under the terms of the law, Ozempic could possibly be subject to cost negotiations by the federal government as early as next 12 months, with recent prices taking effect in 2027. The negotiated unit price would apply to all types of the drug &#8211; Ozempic, its higher-dose weight-loss version Wegovy, and a pill called Rybelsus.</p>
<p class="krtText">It is unclear how high the worth can be. Wegovy costs patients in Denmark as much as $365 a month, which normally doesn&#8217;t cover the fee of the drug – and about <a href="https://www.morningstar.com/news/marketwatch/20240528139/novo-nordisk-blames-middlemen-in-us-healthcare-system-for-high-prices-of-weight-loss-drugs-wegovy-and-ozempic">140 $ in Germany</a> and $92 within the UK</p>
<figure class="wp-caption alignnone"><img decoding="async" class="wp-image-10939926 size-large" src="https://www.mercurynews.com/wp-content/uploads/2024/08/GettyImages-2150033257.jpg" alt="Weight loss drug Wegovy approved under Medicare despite heart health price tag" width="1024" height="680"><figcaption class="wp-caption-text">In this archival photo illustration, the injectable weight reduction drug Wegovy can be available on the New City Halstead Pharmacy in Chicago, Illinois, starting April 24, 2024. (Photo illustration by Scott Olson/Getty Images) </figcaption></figure>
<p class="krtText">Meanwhile, generic drugmakers are preparing to sell their versions of semaglutide, that are expected to hit the market in China and Brazil as early as 2026. In the U.S., Americans will likely must wait until not less than 2032 because of patent restrictions within the U.S. The Federal Trade Commission has sought to shorten the drugs&#39; exclusivity periods by difficult Novo Nordisk&#39;s patent applications for applicators used to inject the drugs &#8211; which might extend their market exclusivity to as much as 30 months.</p>
<p class="krtText">Currently, patients who cannot afford or don&#8217;t have access to the drugs often resort to ready-made preparations that will not be FDA-approved, although their raw materials come from FDA-registered factories. Blaha has &#8220;a number of patients&#8221; who don&#8217;t have access to the brand-name drugs and are available to the clinic with vials of ready-made preparations.</p>
<p class="krtText">Two weeks before Sanders published his letter in Denmark, Novo Nordisk cut the local price of Ozempic by 34 percent to $130 a month &#8211; about 15 percent of the U.S. list price. The government, which had threatened to stop covering the drug, agreed to cover the fee of Ozempic diabetes treatment, but just for patients who had previously tried a less expensive drug equivalent to metformin.</p>
<p class="krtText">Wegovy, the identical weight-loss drug in higher doses, would must be paid for by the patient in just about all cases. The monthly cost is $365. That price, while moderate by U.S. standards, has sparked heated debate in regards to the unequal impact of social class on the affordability of the drug, says Nils Jakob Knudsen, an endocrinologist in Copenhagen.</p>
<p class="krtText">Calculating drug prices is complex for the Danes, he added, because &#8220;the booming economy for Novo also drives our very healthy Danish economy.&#8221;</p>
<p class="krtText">Novo Nordisk&#39;s market valuation of $591 billion on August 2 was significantly higher than Denmark&#39;s entire GDP.</p>
<hr>
<p class="krtText">
<p class="krtText">©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.</p>
<p>Originally published: <time datetime="2024-08-17 03:30:35">August 17, 2024 at 3:30 am</time></p>
</div>
<p><em>image credit : www.mercurynews.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://www.mercurynews.com/wp-content/uploads/2024/08/US-NEWS-HEALTH-DENMARK-OZEMPIC-GET.jpg?w=1024&#038;h=684" medium="image"></media:content>
	</item>
		<item>
		<title>Healthy returns: Eli Lilly gains momentum against Novo Nordisk in weight-loss drug market</title>
		<link>https://bloggingthree.soflytech.com/2024/08/healthy-returns-eli-lilly-gains-momentum-against-novo-nordisk-in-weight-loss-drug-market/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 15 Aug 2024 15:06:32 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[Eli]]></category>
		<category><![CDATA[gains]]></category>
		<category><![CDATA[healthy]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[momentum]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[returns]]></category>
		<category><![CDATA[weightloss]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=12009</guid>

					<description><![CDATA[Novo Nordisk And Eli Lilly currently dominate the booming marketplace for a category of medicine for weight reduction and diabetes. But Eli Lilly may regularly gain a bonus over its Danish competitor within the battle for growing demand for these treatments, also referred to as GLP-1. This became clear last week after the 2 corporations [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="SpecialReportArticle-ArticleBody-6" data-module="ArticleBody" data-test="articleBody-2" data-analytics="SpecialReportArticle-articleBody-6-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-2">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-3">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    currently dominate the booming marketplace for a category of medicine for weight reduction and diabetes. </p>
<p>But Eli Lilly may regularly gain a bonus over its Danish competitor within the battle for growing demand for these treatments, also referred to as GLP-1. </p>
<p>This became clear last week after the 2 corporations announced their respective second-quarter results. </p>
<p>&#8220;Lilly is pulling ahead in the metabolic duopoly,&#8221; Evan Seigerman, an analyst at BMO Capital Markets, said in a research note on Thursday. </p>
<p>On August 7, Novo Nordisk revised down its full-year earnings forecast after the corporate reported that quarterly sales of its weight-loss injectable Wegovy were well below Wall Street expectations. The disappointing result was on account of higher-than-expected price concessions to pharmacy profit managers, who negotiate drug discounts with manufacturers on behalf of insurers, executives said on a conference call last week. </p>
<p>Revenues from the successful diabetes drug Ozempic also fell in need of expectations for this era. The company&#39;s shares plummeted. </p>
<p>Nevertheless, Novo Nordisk has barely raised its forecast for sales growth for the total 12 months. </p>
<p>Eli Lilly&#39;s quarterly report a day later was a really different story. The Indianapolis-based company&#39;s weight-loss drug Zepbound and diabetes drug Mounjaro beat second-quarter expectations.</p>
<p>Eli Lilly raised its 2024 revenue forecast by $3 billion and increased its full-year earnings forecast on account of strong performance from Zepbound and Mounjaro, in addition to “improved clarity” regarding the corporate’s manufacturing expansions for those drugs. </p>
<p>Unlike Novo Nordisk, Eli Lilly benefited from higher U.S. prices for Mounjaro within the quarter as use of savings card programs for the drug declined. Executives said they expect &#8220;stable pricing&#8221; for Mounjaro and Zepbound within the last two quarters of 2024. </p>
<p>Eli Lilly shares closed greater than 9% higher on Thursday. </p>
</div>
<div class="group">
<p>Some analysts were particularly pleased with Eli Lilly&#39;s positive production numbers. Demand for weight-loss and diabetes drugs outstrips supply within the U.S., so corporations that may quickly deliver large quantities of a product to patients can gain a bonus on this area.</p>
<p>All doses of Mounjaro and Zepbound at the moment are listed as available within the U.S. Food and Drug Administration&#39;s drug shortage database. Some doses of Wegovy at the moment are only available in limited quantities as Novo Nordisk invests billions in expanding its own production. </p>
<p>In a research note Thursday, Bank of America analysts raised their combined revenue forecast for Mounjaro and Zepbound to $19.7 billion in 2024, $31 billion in 2025 and $38.5 billion in 2026 as they &#8220;have become more familiar with supply dynamics.&#8221; </p>
<p>The analysts said there could still be temporary supply shortages of Mounjaro and Zepbound within the near future &#8220;as access improves and physicians become more comfortable with the availability of the products.&#8221; But they praised Eli Lilly&#39;s progress in expanding its manufacturing capability and provide. </p>
<p>For example, Eli Lilly CEO David Ricks said in a conference call on Thursday that the corporate has built six manufacturing plants, a few of that are already in operation, and hired hundreds of staff to extend production. The company acquired one other site earlier this 12 months.</p>
<p>Eli Lilly expects production of incretin drugs &#8211; one other term for weight reduction and diabetes treatments &#8211; to be 50% higher within the second half of 2024 than in the identical period last 12 months, he added.  </p>
<p>Ricks said Eli Lilly&#39;s ability to extend production of Zepbound and Mounjaro gives the corporate confidence to compete with latest entrants in the load loss and diabetes drug market that won&#8217;t have the identical capability.</p>
<p>“I don’t know if it’s an obstacle, but it’s certainly work to scale production,” Ricks said. </p>
<p>&#8220;You&#39;re talking about making things on a billion-dollar scale, which takes time, is technically difficult and very capital intensive,&#8221; he continued. &#8220;So of course competitors will have to come. But there is still a long way to go for all these [other drugmakers] that the two leading companies have already gone large parts of it.”</p>
<p>Please send tips, suggestions, story ideas and data to Annika at <a href="http://nbcuni.com/?__source=newsletter%7Chealthyreturns" goal="_blank" rel="noopener">annikakim.constantino@nbcuni.com</a>.</p>
</div>
<h2 class="ArticleBody-subtitle"><a id="headline0"></a>Health technology news: Stryker acquires AI startup Care.ai</h2>
<div class="group">
<p>Medical technology company Stryker announced on Monday that it has agreed to acquire Care.ai, another deal in the field of artificial intelligence in the healthcare sector. </p>
<p>Care.ai uses tools such as AI-powered sensors to help doctors monitor patients and workflows in hospitals, nursing homes and assisted living facilities. The company has <a href="https://www.care.ai/careai-secures-27m-crescent-cove-advisors.html?__source=newsletter%7Chealthyreturns" goal="_blank" rel="noopener">27 million US dollars</a> by Crescent Cove Advisors in 2022.</p>
<p>Stryker offers medical and surgical devices, as well as a range of products in the orthopedics and neurotechnology sectors. The company said technologies like Care.ai&#39;s are &#8220;increasingly vital&#8221; as healthcare organizations grapple with challenges such as nursing shortages, burnout, administrative burdens and workplace safety concerns, according to a <a href="https://www.stryker.com/us/en/about/news/2024/stryker-announces-definitive-agreement-to-acquire-care-ai--a-lea.html?__source=newsletter%7Chealthyreturns" goal="_blank" rel="noopener">Release Monday</a>. </p>
<p>Terms of the transaction were not disclosed, and Stryker said the acquisition was subject to customary closing conditions. </p>
<p>Stryker shares were largely unchanged on Tuesday. </p>
<p>&#8220;Care.ai will help Stryker significantly advance our IT and digital vision in healthcare and supply our customers with intelligent and connected real-time decision support that improves the lives of caregivers and their patients,&#8221; said Andy Pierce, group president of MedSurg and Neurotechnology at Stryker, in the press release.</p>
<p>The technology offered by Care.ai will integrate &#8220;seamlessly&#8221; with Stryker&#39;s platforms and devices, the company added. </p>
<p>“Our commitment to simplifying and improving the lives of healthcare professionals and patients remains unwavering,” said Chakri Toleti, founder and CEO of Care.ai, in a <a href="https://www.linkedin.com/posts/chakritoleti_strykerinnovation-makinghealthcarebetter-activity-7228771413216628736-ckZr?utm_source=share&amp;utm_medium=member_desktop&amp;__source=newsletter%7Chealthyreturns" goal="_blank" rel="noopener">Post on LinkedIn</a>“Together, we are transforming healthcare and ensuring that the well-being of those who need care and those dedicated to caring for others always remains our top priority.”</p>
<p>Stryker declined to comment. Care.ai did not immediately respond to CNBC&#39;s request for comment. </p>
<p>Read the full announcement <a href="https://www.stryker.com/us/en/about/news/2024/stryker-announces-definitive-agreement-to-acquire-care-ai--a-lea.html?__source=newsletter%7Chealthyreturns" goal="_blank" rel="noopener">Here</a>.</p>
<p>Feel free to send suggestions, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108018062-1723129535438-gettyimages-2126120280-ZEPBOUND_PATIENT_SHORTAGES.jpeg?v=1723648940&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Novo Nordisk share price falls as Wegovy maker reports profit decline and lowers operating profit forecast</title>
		<link>https://bloggingthree.soflytech.com/2024/08/novo-nordisk-share-price-falls-as-wegovy-maker-reports-profit-decline-and-lowers-operating-profit-forecast/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sat, 10 Aug 2024 14:48:42 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[decline]]></category>
		<category><![CDATA[falls]]></category>
		<category><![CDATA[forecast]]></category>
		<category><![CDATA[lowers]]></category>
		<category><![CDATA[maker]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[operating]]></category>
		<category><![CDATA[Price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[share]]></category>
		<category><![CDATA[Wegovy]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=11528</guid>

					<description><![CDATA[Novo Nordisk reported weaker-than-expected second-quarter net profit on Wednesday and revised down its operating profit forecast. The pharmaceutical giant said its net profit for the three months to the top of June was 20.05 billion Danish kroner ($2.93 billion), compared with an overall forecast by LSEG of 20.9 billion Danish kroner. EBIT (earnings before interest [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Novo Nordisk reported weaker-than-expected second-quarter net profit on Wednesday and revised down its operating profit forecast.</p>
<p>The pharmaceutical giant said its net profit for the three months to the top of June was 20.05 billion Danish kroner ($2.93 billion), compared with an overall forecast by LSEG of 20.9 billion Danish kroner.</p>
<p>EBIT (earnings before interest and taxes) amounted to DKK 25.93 billion within the second quarter, also below the LSEG forecast of DKK 26.86 billion.</p>
<p>Novo Nordisk also lowered its operating profit forecast for the complete 12 months 2024<strong>, </strong>Growth is now expected to be between 20 and 28 percent as an alternative of the previously expected range of twenty-two to 30 percent.</p>
<p>Novo Nordisk shares fell by almost 7 percent at one point, but were then capable of make up for his or her losses and were last trading at 9:40 a.m. London time, down 2.71 percent.</p>
</div>
<div role="region" aria-labelledby="Placeholder-ArticleBody-Video-108017309">
<div role="button" tabindex="0" id="Placeholder-ArticleBody-Video-108017309" class="PlaceHolder-wrapper" data-vilynx-id="7000347955" data-test="VideoPlaceHolder">
<div class="InlineVideo-videoEmbed" id="InlineVideo-0" data-test="InlineVideo">
<div class="InlineVideo-wrapper">
<div class="InlineVideo-inlineThumbnailContainer"><img decoding="async" class="InlineVideo-videoThumbnail" src="https://image.cnbcfm.com/api/v1/image/108017310-17230198471723019844-35714155546-1080pnbcnews.jpg?v=1723019846&#038;w=750&#038;h=422&#038;vtcrop=y" alt="Novo Nordisk is facing “attractive” growth, says CEO"><span class="InlineVideo-videoButton"></span><span></span></div>
</div>
</div>
</div>
</div>
<div class="group">
<p>In the primary quarter of 2024, the Wegovy maker reported a 28% increase in net profit to DKK 25.4 billion year-on-year, barely increasing its forecasts for sales and operating profit growth.</p>
<p>Expectations for sales growth were raised again on Wednesday. The company now issued a forecast of twenty-two to twenty-eight percent at constant exchange rates for the complete 12 months 2024. Previously, the sales growth forecast for this era had been estimated at 19 to 27 percent.</p>
<p>Sales of the favored weight-loss drug Wegovy increased by 55% within the second quarter of 2024 in comparison with the identical period in 2023, reaching 11.66 billion crowns.</p>
<p>Lars Fruergaard Jørgensen, CEO of Novo Nordisk, said on Wednesday that the corporate expects “attractive growth” in the approaching months.</p>
<p>&#8220;We are very confident that we can scale and also serve patients and now achieve stronger growth for the second half of the year. So I say, worry less about what is happening specifically in [the second quarter]there have been some adjustments in discounts etc., look at our forecast and we believe there is very attractive growth ahead,&#8221; he told CNBC&#39;s &#8220;Street Signs Europe.&#8221;</p>
<p>Novo Nordisk faces increasing competition within the weight-loss space from each smaller corporations and pharmaceutical giants akin to Roche, which last month released promising results from early-stage testing of its own potential obesity drug.</p>
<p>Jørgensen said that while the initial test data may attract attention, it might not impact Novo Nordisk&#39;s business within the short term. Referring to Novo Nordisk&#39;s product pipeline, the CEO said he stays &#8220;very confident&#8221; that the corporate can &#8220;remain competitive in the long term.&#8221;</p>
<p>Novo Nordisk&#39;s Wegovy has also brought promising news in recent months. The drug was approved in China within the second quarter, making it available on the earth&#39;s second-largest economy. Elsewhere, British and European health authorities said they might back Wegovy since it could reduce the chance of great heart problems in chubby and obese adults.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108016749-1722948009130-gettyimages-2141945373-porzycki-wegovyph240408_npnYd.jpeg?v=1722948051&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>These pharmaceutical corporations are catching up with Eli Lilly and Novo Nordisk within the treatment of weight reduction</title>
		<link>https://bloggingthree.soflytech.com/2024/07/these-pharmaceutical-corporations-are-catching-up-with-eli-lilly-and-novo-nordisk-within-the-treatment-of-weight-reduction/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sun, 28 Jul 2024 13:47:03 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[catching]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Eli]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[weight]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=10240</guid>

					<description><![CDATA[The lucrative weight-loss drug market won&#39;t remain a duopoly eternally. With billions at stake, that was all but guaranteed from the beginning for current leaders Eli Lilly and Novo Nordisk. But the fact of the approaching competition has grow to be more tangible following recent announcements from rival pharmaceutical corporations Roche and Viking Therapeutics. Both [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2">
<p><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="xyz-data">The lucrative weight-loss drug market won&#39;t remain a duopoly eternally. With billions at stake, that was all but guaranteed from the beginning for current leaders Eli Lilly and Novo Nordisk. But the fact of the approaching competition has grow to be more tangible following recent announcements from rival pharmaceutical corporations Roche and Viking Therapeutics. Both corporations have made progress with experimental treatments designed to assist patients shed more kilos, faster. Their news is prone to be followed by more in the approaching months as today&#39;s incumbents develop their very own next-generation weight-loss treatments. Still, the headlines have taken their toll. Over the past two weeks, Eli Lilly has lost about $123 billion in market value, posting its worst eight-day decline because the eight days ending March 23, 2020, when its stock fell 15%. During the identical period, Novo Nordisk shares fell about 10%, the worst eight days since mid-August 2022, when its stock plunged 11.4%. Despite that recent pullback, each stocks have posted massive gains this yr: Lilly is up 38%, Novo is down nearly 23%. Some of the recent selling can have been because of investors taking some profits after an extended, regular run. In fact, an identical trend is obvious within the megacap technology stocks which have led the broader stock market&#39;s gains this yr. LLY YTD-Mount of Eli Lilly shares year-to-date. Analysts say Indianopolis-based Lilly and Denmark&#39;s Novo have a large enough lead within the anti-obesity category to make sure growth for a very long time. UBS analyst Trung Huynh doesn&#39;t expect competition to enter the market until around 2028. Even then, rivals shall be limited to not more than 10% of the market by 2029, Huynh said. On Monday, UBS raised its forecast for the GLP-1 (glucagon-like peptide 1) market, predicting it can grow 33% annually through 2029 and reach $150 billion in revenue by 2029, in comparison with a previous forecast of $125 billion. The reason for the upper estimate is the expectation that more individuals with obesity will seek treatment, UBS said in a research note. Other analysts have also grow to be more optimistic concerning the way forward for weight reduction treatments. &#8220;As clinical data accumulates on cardiovascular risk, kidney disease and other risk-reducing comorbidities, we believe the pace of access and adoption will increase,&#8221; said Rajesh Kumar, an analyst at HSBC Global Research. Kumar said concerns about competition are &#8220;valid&#8221; but &#8220;too early.&#8221; &#8220;It is true that many players are developing assets targeting obesity,&#8221; he said. &#8220;However, the time required to build clinical data, access and manufacturing scale remains the key barrier to entry.&#8221; Meanwhile, analysts say Lilly and Novo could proceed to deliver positive surprises as they work to ramp up their manufacturing capacities. Demand for weight-loss drugs far exceeds supply. How the competition stacks up: Roche&#39;s recent announcements suggest the corporate could grow to be the third major company to enter the anti-obesity drug market. On July 17, the Swiss company announced that CT-996, a once-daily oral GLP-1 drug it acquired through the acquisition of Carmot Therapeutics, helped obesity patients lose a median of 6.1 percent of their baseline weight in 4 weeks in a Phase 1 clinical trial. That was a formidable result. Orforglipron, a once-daily oral GLP-1 drug that Lilly is working on, had shown 3 percent weight reduction after 4 weeks. Many had hoped for an efficient oral GLP-1 treatment, since each Novo&#39;s Wegovy and Lilly&#39;s Zepbound are given as a once-weekly injection. Patients typically prefer taking a pill over a shot, and tablets are likely to be inexpensive to supply. Roche will advance CT-996 right into a Phase 2 trial next yr while continuing to review CT-388, which is given by a weekly injection. The company can also be considering whether combination therapies make sense, which could expand the marketplace for the drugs. Roche&#39;s ADRs are up 12.5% ​​to this point in 2024. VKTX YTD-mount of Viking Therapeutics shares year-to-date. Viking Therapeutics rose 30% last week after the corporate announced following a gathering with the Food and Drug Administration that VK-2735 &#8211; an injectable drug that mixes two gut hormones, GLP-1 and GIP (gastric inhibitory polypeptide) &#8211; would move directly right into a Phase 3 program. The company can also be exploring whether the weight-loss drug might be administered as little as once a month. BTIG analyst Justin Zelin said Viking seems &#8220;increasingly confident&#8221; that monthly dosing is feasible, a feat he said could be &#8220;icing on the cake.&#8221; Like Lilly and Novo, Viking is working on an oral drug that can move right into a Phase 2 trial within the fourth quarter. Zelin expects to supply more details on the trials on the ObesityWeek conference in San Antonio in early November. He rates Viking stock a buy and has a $125 price goal, barely above Wall Street&#39;s $114 average price goal, in line with FactSet. Even with Viking&#39;s sharp rise last week, the stock has 89% upside potential if it hits Zelin&#39;s goal. More News to Come More progress in GLP-1 is predicted within the second half of the yr, which is able to further boost Lilly and Novo shares. Two big events on the calendar are a European Association for the Study of Diabetes conference in Spain in mid-September and ObesityWeek two months later. HSBC&#39;s Kumar has identified at the very least 125 drug candidates to treat obesity in various stages of development. The market has heard news recently from players like Pfizer and Amgen, in addition to Structure Therapeutics and Altimmune. And Lilly and Novo aren&#39;t sitting still, either. Kumar expects a fourth-quarter release of Novo&#39;s next-generation drug, CagriSema, to &#8220;defuse Novo&#39;s long-term growth potential.&#8221;  Below is a table of a few of the clinical trials that investors expect to listen to news about later this yr. —CNBC&#39;s Nick Wells contributed to this report.</span></span></span><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107378853-1709040141961-gettyimages-1665778558-img_5416-1.jpeg?v=1722022688&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Novo Nordisk shares ignore concerns over study linking weight-loss drugs to rare eye disease</title>
		<link>https://bloggingthree.soflytech.com/2024/07/novo-nordisk-shares-ignore-concerns-over-study-linking-weight-loss-drugs-to-rare-eye-disease/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 04 Jul 2024 12:09:50 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[eye]]></category>
		<category><![CDATA[ignore]]></category>
		<category><![CDATA[linking]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[weightloss]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=8110</guid>

					<description><![CDATA[Novo Nordisk investors were unimpressed on Thursday by a critical Harvard report that linked weight-loss drugs to a rare eye disease. Semaglutide, which is contained in weight-loss drugs equivalent to Ozempic and Wegovy from Novo Nordisk, could also be linked to an increased risk of a rare eye disease, in accordance with a study conducted [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Novo Nordisk investors were unimpressed on Thursday by a critical Harvard report that linked weight-loss drugs to a rare eye disease.</p>
<p>Semaglutide, which is contained in weight-loss drugs equivalent to Ozempic and Wegovy from Novo Nordisk, could also be linked to an increased risk of a rare eye disease, in accordance with a <a href="https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2820255" target="_blank" rel="noopener">study</a> conducted by Harvard Medical School.</p>
<p>However, analysts said the trial results were &#8220;hardly groundbreaking.&#8221; Shares within the Danish pharmaceutical company were unchanged on Thursday, slipping in morning trade and rising 0.1 percent at 11:17 a.m. London time.</p>
<p>The Harvard report found that patients with type 2 diabetes or obesity who&#8217;re prescribed semaglutide have an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) &#8211; a condition that may result in lack of vision in a single eye. Patients were diagnosed with the attention condition more often than those that weren&#8217;t prescribed the weight-loss drugs, the study found.</p>
<p>Although the research suggests &#8220;some connection&#8221; to a rare eye event, the standard of the evidence is &#8220;very low and the margin for error very high,&#8221; said Emmanuel Papadakis, an analyst at Deutsche Bank.</p>
<p>The worst-case scenario would likely be one other update to the warnings on drug labels, but that may &#8220;hardly be a groundbreaking change,&#8221; Papadakis said.</p>
<p>He added that Deutsche Bank generally views semaglutide drugs as &#8220;one of the lowest-risk classes of therapy in the history of the industry.&#8221;</p>
<p>A Novo Nordisk spokesman said the optic nerve disease<strong> </strong>NATIONAL<strong> </strong>will not be an &#8220;adverse reaction for the commercially available formulations of semaglutide,&#8221; in accordance with the approved labels. They added that there have been &#8220;important methodological limitations&#8221; of the study, equivalent to the &#8220;small number of people&#8221; with type 2 diabetes or obesity who were exposed to semaglutide and included within the study.</p>
<p>“Patient safety is Novo Nordisk’s highest priority and we take all reports of adverse reactions related to the use of our medicines very seriously,” the spokesman said.</p>
</div>
<div role="region" aria-labelledby="Placeholder-ArticleBody-Video-107409276">
<div role="button" tabindex="0" id="Placeholder-ArticleBody-Video-107409276" class="PlaceHolder-wrapper" data-vilynx-id="7000339030" data-test="VideoPlaceHolder">
<div class="InlineVideo-videoEmbed" id="InlineVideo-0" data-test="InlineVideo">
<div class="InlineVideo-wrapper">
<div class="InlineVideo-inlineThumbnailContainer"><img decoding="async" class="InlineVideo-videoThumbnail" src="https://image.cnbcfm.com/api/v1/image/107409289-1714637582782-1714635393-34357197207-hd.jpg?v=1714637585&#038;w=750&#038;h=422&#038;vtcrop=y" alt="Novo Nordisk reported “exceptional growth” but faces a competitive weight loss market: Novasecta"><span class="InlineVideo-videoButton"></span><span></span></div>
</div>
</div>
</div>
</div>
<div class="group">
<p>The popularity of its blockbuster drugs has made Novo Nordisk the most useful company in Europe; its valuation last yr was higher than Denmark&#39;s entire gross domestic product.</p>
<p>Wegovy also has health advantages beyond weight reduction and blood sugar regulation. The Food and Drug Administration approved it in March to scale back the chance of heart disease.</p>
<p>However, the drugs have come under fire after some patients reported experiencing stomach paralysis and suicidal thoughts while taking the drugs. A study by researchers on the University of British Columbia found an increased risk of intestinal obstruction, a condition during which food is prevented from passing through the small or large intestine, and pancreatitis, or inflammation of the pancreas.</p>
<p>The labels of the medicines already contain warnings about <a href="https://www.wegovy.com/taking-wegovy/side-effects.html#:~:text=the%20stomach%20quickly.-,What%20are%20the%20possible%20side%20effects%20of%20Wegovy%C2%AE%3F,away%2C%20with%20or%20without%20vomiting." target="_blank" rel="noopener">Pancreatitis</a> And <a href="https://www.healthline.com/health-news/fda-updates-ozempic-label-to-include-blocked-intestines-as-potential-side-effect#How-to-identify-and-help-prevent-blocked-intestines-while-taking-Ozempic" target="_blank" rel="noopener">certain types</a> of intestinal obstruction. A change in vision can also be listed as a possible side effect of each Ozempic and Wegovy.</p>
<p>The US study, published on Wednesday, analyzed data from 16,827 patients from December 2017 to November last yr. The researchers identified that further studies are needed to find out whether semaglutide causes the attention disease.</p>
</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107393001-17114709252023-03-29t000000z_1653336606_rc2w30aoohoj_rtrmadp_0_usa-health.jpeg?v=1711470985&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Novo Nordisk increases production of Wegovy and Ozempic with recent NC plant</title>
		<link>https://bloggingthree.soflytech.com/2024/06/novo-nordisk-increases-production-of-wegovy-and-ozempic-with-recent-nc-plant/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Tue, 25 Jun 2024 06:20:51 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[Ozempic]]></category>
		<category><![CDATA[plant]]></category>
		<category><![CDATA[production]]></category>
		<category><![CDATA[Wegovy]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=7235</guid>

					<description><![CDATA[Novo Nordisk announced Monday that the corporate would invest $4.1 billion to construct a brand new manufacturing facility in Clayton, North Carolina, to extend supply of its successful weight-loss drug Wegovy, diabetes drug Ozempic and other injectable therapies. Demand for Wegovy and Ozempic exceeded supply last 12 months, resulting in temporary shortages within the US [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    announced Monday that the corporate would invest $4.1 billion to construct a brand new manufacturing facility in Clayton, North Carolina, to extend supply of its successful weight-loss drug Wegovy, diabetes drug Ozempic and other injectable therapies. </p>
<p>Demand for Wegovy and Ozempic exceeded supply last 12 months, resulting in temporary shortages within the US and forcing the Danish pharmaceutical company to take a position heavily in expanding its production capability. The company announced it could invest $6.8 billion in production this 12 months, up from around $4 billion last 12 months. </p>
<p>The recent production facility shall be chargeable for filling and packaging syringes and injection pens for the medications, the corporate said in a press release. </p>
<p>&#8220;This investment really gives us the opportunity to serve more patients,&#8221; Doug Langa, head of Novo Nordisk&#39;s North American business, said in an interview. &#8220;The other important message, I think, is that this is further investment in the U.S., and I think we&#39;re very proud of that.&#8221;</p>
<p>Construction of the 1.4 million square meter facility has begun and is predicted to be accomplished between 2027 and 2029, Novo Nordisk said. The company said 1,000 staff shall be employed at the development site, along with the two,500 employees already working at the power. <a href="https://www.novonordisk-us.com/about/who-we-are/north-carolina.html" target="_blank" rel="noopener">three existing production facilities</a> in North Carolina. </p>
<p>These include two <a href="https://www.novonordisk-us.com/about/who-we-are/north-carolina.html" target="_blank" rel="noopener">Locations already in operation in Clayton</a> — one is chargeable for filling and ending, one other for manufacturing the energetic ingredient for the corporate&#39;s diabetes drug Rybelsus. The company also has a site in Durham, North Carolina, chargeable for manufacturing and packaging oral medications, and one other facility in West Lebanon, New Hampshire.</p>
</div>
<div class="group"></div>
<div class="group">
<p>Twelve other production sites are positioned in Denmark, France, China, Japan, Algeria, Brazil, Iran and Russia, in line with a Novo Nordisk spokesman.</p>
<p>According to a press release from the U.S. Food and Drug Administration, three lower doses of Wegovy are currently in brief supply within the United States as a result of high demand <a href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&amp;st=c" target="_blank" rel="noopener">Database</a>Patients start with a lower dose of Wegovy and steadily increase the quantity every 4 weeks until they reach the goal dose.</p>
<p>Wegovy and Ozempic belong to a category of medicine called GLP-1, which mimic hormones produced within the gut to suppress an individual&#39;s appetite and regulate their blood sugar.</p>
<p>Today, a mean of about 35,000 U.S. patients are beginning to take Wegovy each week, up from about 27,000 in May, a Novo Nordisk spokesperson said in a press release. Still, Langa said the corporate is being &#8220;very intentional&#8221; in regards to the variety of lower doses it brings to the U.S. market to make sure patients who&#8217;ve already began taking Wegovy can proceed treatment with higher doses.</p>
<p>Competing pharmaceutical company <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-7">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    has also invested billions of dollars to extend manufacturing capability for its popular GLP-1 weight reduction and diabetes products, Zepbound and Mounjaro. The company also has several manufacturing facilities in North Carolina. </p>
</div>
<div class="group"></div>
<div class="group">
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107432310-1719254833440-107432310-1719241933858-NOVONORDISKCLAYTONSITE.jpg?v=1719264008&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Healthy Yields: Eli Lilly and Novo Nordisk are making progress in increasing their offerings of weight-loss medications</title>
		<link>https://bloggingthree.soflytech.com/2024/05/healthy-yields-eli-lilly-and-novo-nordisk-are-making-progress-in-increasing-their-offerings-of-weight-loss-medications/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Wed, 08 May 2024 07:42:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Eli]]></category>
		<category><![CDATA[healthy]]></category>
		<category><![CDATA[Increasing]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[making]]></category>
		<category><![CDATA[medications]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[offerings]]></category>
		<category><![CDATA[progress]]></category>
		<category><![CDATA[weightloss]]></category>
		<category><![CDATA[Yields]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=2877</guid>

					<description><![CDATA[Good day! An extremely popular group of weight reduction and diabetes medications continues to be difficult to search out within the United States. The dominant manufacturers of those treatments, Eli Lilly And Novo Nordiskare making progress to vary that. But Wall Street seems more encouraged by one than the opposite. The drugmakers provided updates on [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="SpecialReportArticle-ArticleBody-6" data-module="ArticleBody" data-test="articleBody-2" data-analytics="SpecialReportArticle-articleBody-6-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Good day!  An extremely popular group of weight reduction and diabetes medications continues to be difficult to search out within the United States.  The dominant manufacturers of those treatments, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-3">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-4">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>are making progress to vary that. </p>
<p>But Wall Street seems more encouraged by one than the opposite.  </p>
<p>The drugmakers provided updates on their offerings after they released their first-quarter financial results.  Demand for his or her weight reduction and diabetes medications has far outstripped supply during the last 12 months, forcing the couple to take a position heavily in expanding their production.</p>
<p>Investors cheered Eli Lilly after the corporate raised its full-year sales forecast by $2 billion, partly on confidence that production of its weight-loss drug Zepbound, diabetes drug Mounjaro and similar drugs will proceed for the remaining of the 12 months will be increased yearly.  The company calls these treatments incretin medications, which mimic certain gut hormones to suppress an individual&#39;s appetite and regulate blood sugar. </p>
<p>&#8220;Now that we&#39;re four months into the year, we have better insight into these capacity nodes and feel more confident,&#8221; Eli Lilly Chief Financial Officer Anat Ashkenazi told investors during an April 30 earnings call.</p>
<p>She noted that Eli Lilly has several manufacturing sites which might be either &#8220;ramped up or under construction,&#8221; including two sites in North Carolina, two in Indiana, one in Ireland and one in Germany.  There can also be a seventh location that the corporate recently acquired from Nexus Pharmaceuticals. </p>
<p>Ashkenazi also highlighted the recent approval and upcoming launch of a brand new Mounjaro delivery device called the KwikPen in Europe <a href="https://www.gov.uk/government/news/four-dose-mounjaro-kwikpen-approved-by-mhra-for-diabetes-and-weight-management" target="_blank" rel="noopener">United Kingdom</a>, which they are saying will “unlock new supply capacity” for certain international markets.  That&#39;s because Eli Lilly has been using this device for insulin for years, allowing the corporate to make use of existing manufacturing resources to make more other incretin medications. </p>
<p>KwikPen is a single four-dose pen that covers one month of treatment.  Patients using topical auto-injectors for weight reduction and diabetes medications<strong> </strong>Go through 4 different pens every month.  Asked whether the corporate would launch the device within the US, Eli Lilly CEO David Ricks told investors: &#8220;We haven&#39;t ruled it out in other jurisdictions.&#8221; </p>
<p>Eli Lilly expects supply of Zepbound, Mounjaro and other incretin drugs to stay &#8220;fairly tight&#8221; within the short to medium term as demand stays high, Ashkenazi said.  However, she noted that Eli Lilly expects production of sellable doses of incretin drugs to be a minimum of 1.5 times higher later this 12 months in comparison with the second half of 2023 &#8211; a goal the corporate is setting for the primary time set out in February. </p>
<p>On the day Eli Lilly announced its earnings, the corporate&#39;s shares rose greater than 5% on the back of raised guidance and offering updates. </p>
<p>&#8220;While [Lilly] “As we continue to expect demand for incretins to exceed supply for the foreseeable future, the company is clearly making progress in expanding capacity and this should be reflected in accelerated volume growth throughout the year,” JPMorgan analyst Chris Schott said. last week in a research note. </p>
</div>
<div class="group">
<p>Meanwhile, investors seemed less impressed with Novo Nordisk last week.  The company&#39;s shares fell more than 2% on May 2 following the release of first-quarter results. </p>
<p>Novo Nordisk executives said in a media call that day that the company is gradually increasing production of weaker or &#8220;starter&#8221; doses of its weight-loss drug Wegovy in the U.S. after limiting its supply last May to meet demand . </p>
<p>About 27,000 new patients in the U.S. are now starting weekly injections each week, CEO Lars Fruergaard Jorgensen said on a media call.  That&#39;s up from 5,000 per week in December. </p>
<p>“This is really a very nice increase in volume, as we had planned,” said Jorgensen. </p>
<p>He added that the company will continue to increase supply of Wegovy and its diabetes counterpart Ozempic for the remainder of the year.  The company&#39;s primary focus is &#8220;ensuring continuity of take care of patients who&#8217;ve already begun treatment,&#8221; Jorgensen said. </p>
<p>Still, Novo Nordisk missed Wall Street&#39;s sales estimates for its weight-loss drug Wegovy, even though supply and prescriptions for the drug increased during the quarter.  According to FactSet, Wegovy&#39;s revenue more than doubled to 9.38 billion Danish kroner ($1.35 billion) in the period, falling short of analysts&#39; expectations of 10.55 billion Danish kroner ($1.52 billion). -dollars) back.</p>
<p>That&#39;s because prices for Wegovy and Ozempic fell in the first quarter as volumes and competition increased, Karsten Munk Knudsen, the company&#39;s CFO, told analysts in a call. </p>
<p>He added that this trend will continue for the rest of the year.  U.S. list prices for Wegovy and Ozempic are still around $1,000 a month, but Novo is offering insurers discounts and rebates to extend coverage to more patients.</p>
<p>We will continue to monitor how the supply landscape changes as the year progresses.  Stay tuned for our reporting.</p>
<p>You can send tips, suggestions, story ideas and data to Annika at <a href="http://annikakim.constantino@nbcuni.com" goal="_blank" rel="noopener">annikakim.constantino@nbcuni.com</a>.</p>
</div>
<h2 class="ArticleBody-subtitle"><a id="headline0"></a>Latest technology in healthcare</h2>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-12">Apple<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    received US Food and Drug Administration approval for its cardiac monitoring technology on May 3. </p>
<p>The Agency <a href="https://www.fda.gov/news-events/press-announcements/fda-roundup-may-3-2024" goal="_blank" rel="noopener">announced</a> Apple Watch&#39;s Atrial Fibrillation History feature can be used in clinical trials through the Medical Device Development Program.  Apple&#39;s feature is the first digital health technology to qualify for the program, the FDA said. </p>
<p>The FDA <a href="https://www.fda.gov/medical-devices/medical-device-development-tools-mddt" goal="_blank" rel="noopener">program</a> identifies technologies that are reliable enough to be used in a scientific research context.  It is a voluntary pathway and the tools and solutions qualified under the MDDT program are then used to help evaluate new medical devices. </p>
<p>Apple&#39;s Atrial Fibrillation History technology will serve as such <a href="https://www.fda.gov/media/178230/download?attachment" goal="_blank" rel="noopener">Biomarker test</a> to evaluate the safety and effectiveness of cardiac ablation devices used to treat irregular heartbeats. </p>
<p>Atrial fibrillation, often called atrial fibrillation, is a type of irregular heart rhythm caused by the organ&#39;s upper chambers beating &#8220;chaotically.&#8221; <a href="https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/symptoms-causes/syc-20350624" goal="_blank" rel="noopener">Mayo Clinic</a>.  Atrial fibrillation often causes a fast, pounding heartbeat and can lead to blood clots and an increased risk of stroke or heart failure. </p>
<p>The disease affects each individual differently and sometimes those affected do not experience any symptoms.  Still, patients with atrial fibrillation usually require treatment such as medication, therapy or surgery to prevent consequences such as stroke, according to the Mayo Clinic. </p>
<p>Apple&#39;s AFib History feature allows users to track how long their heart is showing signs of AFib over time <a href="https://support.apple.com/en-us/HT212214" goal="_blank" rel="noopener">Company website</a>.  The feature is not intended for anyone under 22 and users must wear their Apple Watch at least 12 hours a day, five days a week to receive quotes.</p>
<p>Users can also share their data with their doctors to determine the right treatments and next steps for them. </p>
<p>AFib History was first approved by the FDA two years ago, and Apple has also done so <a href="https://support.apple.com/en-us/HT212214" goal="_blank" rel="noopener">step by step</a> Instructions online for patients interested in the facility.  </p>
<p>Feel free to send tips, suggestions, story ideas and data to Ashley <a href="http://ashley.capoot@nbcuni.com" goal="_blank" rel="noopener">ashley.caroot@nbcuni.com</a>.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="SpecialReportArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these exclusives from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107368557-17069062502023-12-13t123425z_1803569422_rc26v4aidh6r_rtrmadp_0_health-obesity-telehealth.jpeg?v=1715113291&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
